Preclinical & Research

BioPharmX plans to strategically expand its pipeline by using its novel drug delivery platforms to identify and create new dermatological products. Several new opportunities leveraging currently approved active pharmaceutical ingredients (APIs) are being evaluated. These include product candidates utilizing our patented HyantX™ delivery platform as well as delivery platforms still in development. Our goal is to advance at least one of our exciting new dermatology product candidates into clinic in 2018.